About WordPress

Search

↓ Skip to Main Content

the new generation glocalized network in theragenomic and personalized medicine and the genetics of patient's individualized drug safety

search: thasso

Search for:

Log in

Main Navigation

english
thasso
thasso: post
thasso: community
thasso: resources
thasso: academy
thasso: about
donations $
Cookie Policy (EU)

Home › Posts tagged Hepatitis C Virus (HCV)

Tag: Hepatitis C Virus (HCV)

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection

By Joseph Gut - thasso Posted on June 29, 2016 Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments Tagged with Genotypes, Hepatitis C Virus (HCV), Liver Cirrhosis, Sofosbuvir/Velpatasvir (Epclusa), Targeted Therapy, Thasso Post, The American Food & Drug Administration (FDA), Theragenomic Medicine

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection

June 29, 2016 – The saga goes on: The American Food & Drug Administration (FDA) just approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) infection both with and without cirrhosis (advanced liver disease). For patients with …

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection Read more »

EMA: Two new combination therapies against chronic hepatitis C recommended for approval

By Joseph Gut - thasso Posted on May 31, 2016 Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments Tagged with European Medicines Agency (EMA), Fixed Combination, Grazoprevir/Elbasvir (Zepatier), Hepatitis C, Hepatitis C Virus (HCV), Sofosbuvir/Velpatasvir (Epclusa)

EMA: Two new combination therapies against chronic hepatitis C recommended for approval

May 30, 2016 – According to its News and Events section of the homepage, the European Medicines Agency (EMA) has recommended the granting of marketing authorisations in the European Union (EU) for two new combination therapies against chronic (long-term) hepatitis C virus (HCV) infection, namely …

EMA: Two new combination therapies against chronic hepatitis C recommended for approval Read more »

Elbasvir/Grazoprevir (Zepatier) for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections

By Joseph Gut - thasso Posted on January 30, 2016 Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments Tagged with Chronic Hepatitis C Virus (HCV) Infection, Elbasvir/Grazoprevir (Zepatier), HCV Genotype 1, HCV Genotype 4, Hepatitis C Virus (HCV), Liver Toxicity

Elbasvir/Grazoprevir (Zepatier) for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections

January 30, 2016 – Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes …

Elbasvir/Grazoprevir (Zepatier) for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections Read more »

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you. Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci. Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

FDA press releases

FDA Roundup: September 30, 2022  September 30, 2022
FDA Pathway Supports Long-Term Stability, Diversity of Safe and Nutritious Infant Formula Supply in the U.S. September 30, 2022
FDA Approves New Treatment Option for Patients with ALS September 29, 2022
FDA, Veterans Health Administration Collaborate to Help Accelerate Medical Device Innovation and Advancement of Care September 28, 2022
FDA Proposes Updated Definition of ‘Healthy’ Claim on Food Packages to Help Improve Diet, Reduce Chronic Disease September 28, 2022

FDA MedWatch

LivaNova (TandemLife) Recalls LifeSPARC System for Risk of Unintentional Extended Pump Stop During Controller Critical Failure September 30, 2022
2022 Medical Device Recalls September 30, 2022
Golden State Medical Supply, Inc. Issues a Voluntary Nationwide Recall of Atenolol 25 mg Tablets and Clopidogrel 75 mg Tablets Due to a Label Mix-up September 29, 2022
Proper Trade LLC/My Stellar Lifestyle Issues Voluntary Nationwide Recall of Wonder Pill Capsules Due to the Presence of Undeclared Tadalafil September 28, 2022
Eugia US LLC Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection 500 mg per 10 mL (50 mg/mL), Due to the Presence of Particulate Matter September 27, 2022

EMA Press releases

Regulatory information – adjusted fees for pharmacovigilance applications from 3 October 2022, , 30/09/2022 September 30, 2022
New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome, PRAC, 30/09/2022 September 30, 2022
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 September 2022, PRAC, 30/09/2022 September 30, 2022
EMA pilot offers enhanced support to academic and non-profit developers of advanced therapy medicinal products , , 29/09/2022 September 29, 2022
New co-chairs elected for working parties for healthcare professionals and for patients and consumers, , 23/09/2022 September 23, 2022

random genetics

Mouse study suggests genetics of longevity are influenced by both gender and age September 30, 2022
A team of researchers affiliated with several institutions in Switzerland and the U.S. reports evidence that the genetics of longevity are influenced by both gender and age. In their paper published in the journal Science, the group describes their study of aging in mice and humans. João Pedro de Magalhães, with the University of Birmingham, […]
Gene loss enhances metastasis and cancer progression September 30, 2022
Investigators have discovered that the loss of the gene SLIT2 in circulating tumor cells regulates metastasis of prostate cancer tumors, according to a Northwestern Medicine study published in Science Advances.
In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis September 29, 2022
Despite recent advancements in our knowledge of the pathogenic mechanisms of ulcerative colitis, there is still a considerable unmet medical need for the treatment of the condition.
Tendons help you sprint, jump and move. A genetic mutation in one key protein may increase athletic performance September 29, 2022
The locomotor, or musculoskeletal, system of the body consists of muscles, bones, tendons, ligaments, joints, cartilage and other connective tissue. Loss of motor function due to disease or injury can result in a lifetime of disability. In a rapidly aging society, maintaining and improving motor function can be a significant challenge for many people.
Breakthrough in understanding of how cancer spreads could lead to better treatments September 29, 2022
Scientists have discovered that cancer cells "hijack" a process used by healthy cells to spread around the body, completely changing current ways of thinking around cancer metastasis.

Recent Comments

David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18
Pamela Erickson on Is genetic testing of value for ALS patients?: “My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 63 years old 4 years ago. The Rilutek…” Aug 13, 13:04
thassodotcom on Unlucky women with BIA-ALCL: An update: “The Therapeutic Goods Agency (TGA) of Australia has just issued a hazard alert concerning the risk of breast implant-associated anaplastic…” Aug 4, 09:17
thassodotcom on Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death: “According to its Drug Safety Communication from 07/26/2019, the FDA has approved new warnings about an increased risk of blood…” Aug 4, 08:40

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Clinical Trial Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Erectile Dysfunction Ethnicity European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Health Canada Non-Small Cell Lung Cancer (NSCLC) Obesity Pembrolizumab [Keytruda] Personalized Medicine Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

thasso

thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide

keys

Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,

meta

Register
Log in
Entries feed
Comments feed
WordPress.org

© 2022 thasso | Powered by Responsive Theme

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

{title} {title} {title}